| Gender |
|
|
0.487 |
| male |
189 |
0.811 ± 0.072 |
|
| female |
219 |
0.806 ± 0.067 |
|
| Vital status |
|
|
0.863 |
| Alive |
311 |
0.808 ± 0.070 |
|
| Dead |
97 |
0.809 ± 0.067 |
|
| Kras mutation found |
|
|
0.866 |
| YES |
16 |
0.801 ± 0.074 |
|
| NO |
34 |
0.797 ± 0.071 |
|
| Pathologic T |
|
|
0.910 |
| T1/T1a/T1b |
127 |
0.810 ± 0.063 |
|
| T2/T2a/T2b |
227 |
0.810 ± 0.069 |
|
| T3 |
36 |
0.794 ± 0.089 |
|
| T4 |
15 |
0.809 ± 0.072 |
|
| TX |
3 |
0.788 ± 0.083 |
|
| Pathologic N |
|
|
0.690 |
| N0 |
261 |
0.806 ± 0.073 |
|
| N1 |
75 |
0.816 ± 0.057 |
|
| N2 |
62 |
0.810 ± 0.069 |
|
| N3 |
1 |
0.855 |
|
| NX |
8 |
0.793 ± 0.048 |
|
| Pathologic M |
|
|
0.552 |
| M0 |
264 |
0.810 ± 0.068 |
|
| M1/M1a/M1b |
17 |
0.815 ± 0.066 |
|
| MX |
123 |
0.803 ± 0.071 |
|
| Pathologic tumor stage |
|
|
0.799 |
| Stage I/IA/IB |
218 |
0.811 ± 0.069 |
|
| Stage IIA/IIB |
102 |
0.803 ± 0.070 |
|
| Stage IIIA/IIIB |
68 |
0.809 ± 0.069 |
|
| Stage IV |
19 |
0.807 ± 0.068 |
|
| Race |
|
|
0.996 |
| WHITE |
325 |
0.809 ± 0.069 |
|
| BLACK OR AFRICAN AMERICAN |
29 |
0.808 ± 0.066 |
|
| ASIAN |
5 |
0.810 ± 0.041 |
|
| Histologic diagnosis |
|
|
0.033 |
| Lung Adenocarcinoma Mixed Subtype |
79 |
0.830 ± 0.058 |
|
| Lung Adenocarcinoma- Not Otherwise Specified (NOS) |
259 |
0.805 ± 0.068 |
|
| Lung Mucinous Adenocarcinoma |
2 |
0.766 ± 0.100 |
|
| Lung Acinar Adenocarcinoma |
13 |
0.802 ± 0.070 |
|
| Lung Bronchioloalveolar Carcinoma Mucinous |
4 |
0.850 ± 0.010 |
|
| Lung Papillary Adenocarcinoma |
17 |
0.819 ± 0.059 |
|
| Lung Micropapillary Adenocarcinoma |
3 |
0.745 ± 0.114 |
|
| Mucinous (Colloid) Carcinoma |
7 |
0.776 ± 0.090 |
|
| Lung Bronchioloalveolar Carcinoma Nonmucinous |
19 |
0.784 ± 0.098 |
|
| Lung Solid Pattern Predominant Adenocarcinoma |
4 |
0.794 ± 0.082 |
|
| Age |
|
|
0.845 |
| ≤60 |
131 |
0.809 ± 0.072 |
|
| >60 |
259 |
0.808 ± 0.067 |
|
| ECOG score |
|
|
0.029 |
| 0 |
79 |
0.804 ± 0.067 |
|
| 1 |
68 |
0.832 ± 0.061 |
|
| 2 |
21 |
0.811 ± 0.064 |
|
